PNPLA3 and Hepatic steatosis: After excluding n = 38 HIV/HCV-GT3 patients for this subgroup analysis, the results were comparable to those obtained from the entire cohort with similar FPR (0.28±0.44 vs. 0.21±0.30, p = 0.838), similar amount of hepatic steatosis (CAP: 200.6±41.6 vs. 196.8±39.8, p = 0.851) and similar degree of portal hypertension (HVPG: 3.5±1.5 vs. 3.6±2.1, p = 0.752) across PNPLA3 genotypes.